<DOC>
	<DOCNO>NCT00559637</DOCNO>
	<brief_summary>This single arm study ass efficacy safety subcutaneous Mircera correction anemia participant chronic kidney disease treat erythropoiesis stimulating agent ( ESA ) dialysis . Eligible participant receive Mircera monthly subcutaneous injection . The initial dose , base body weight , 1.2 micrograms/kilogram ( mcg/kg ) . The anticipated time study treatment 9-11 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Subcutaneous Mircera Participants With Chronic Kidney Disease Not Treated With ESA Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>chronic renal anemia ; hemoglobin value less equal ( &lt; = ) 10.5 grams/deciliter ( g/dL ) . prior ESA therapy previous 3 month ; acute chronic bleed require therapy previous 2 month ; transfusion red blood cell previous 2 month ; active malignant disease ( except nonmelanoma skin cancer ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>